Celiac Disease Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (Vitamins And Dietary Supplements, Steroids And Immunosuppressive Drugs, Therapeutic Vaccines), And By Geography - Forecasts From 2021 To 2026

  • Published : Nov 2021
  • Report Code : KSI061610419
  • Pages : 114

The celiac disease treatment market is expected to grow at a compound annual growth rate of 14.45% over the forecast period to reach a market size of US$561.677 million in 2026 from US$218.303 million in 2019.


Celiac disease is a digestive disorder that makes it difficult for the body to absorb nutrients like fat, calcium, iron, and folate. Celiac disease is an autoimmune disease. Patients suffering from this disease have damaged lining of the small intestine owing to consumption of foods with gluten. Celiac diseases, being gene-based, are inherited by people, especially those having a family history of type 1 diabetes, autoimmune thyroid, down syndrome, rheumatoid arthritis, microscopic colitis, and Addison’s disease. The market for celiac disease treatment is projected to observe lucrative growth during the forecast period. The prime driver driving the growth in the market is robust growth in the development of various anti-inflammatory drugs and therapeutic vaccines which are expected to substitute for a gluten-free diet. Rising healthcare expenditure and investment have resulted in growing medical research which has fueled the market. furthermore, increasing awareness about the disease and steps taken by healthcare organization to spread awareness is expected to further bolster this growth. Geographically, Europe and North America's celiac disease treatment markets are the largest. High prevalence and a well-established healthcare landscape support the industry in these regions. Africa, on the other hand, is a market with great potential, given the fact that the highest prevalence of the disease is found in the Saharawi people of Africa.

Market Trends.

The rising adoption of therapeutic products in developed and developing economies is a crucial factor that is expected to escalate market growth. Growing healthcare awareness and steps taken by various healthcare organizations have led to increasing health consciousness and also rising diabetes cases. Growing healthcare expenditure has encouraged favourable government policies across the world. Increased investment has raised the number of clinical trials for drugs against celiac disease. Increased consumption of foods such as fast food, ready-to-eat food, packed food, and others that are high in protein has increased gluten consumption which leads to celiac disease, increasing change in the trends in restaurants that offer ready-to-eat packaged foods, junk food, and beverage addiction, changing lifestyle, and increasing disposable income adds to the gluten intake which is a major factor drives the growth of celiac disease treatment market. Moreover, rising technological advancements and increasing modernization in the healthcare sector, and rising research and development activities will further create new opportunities for the celiac disease treatment market in the upcoming years.

However, limited availability of the treatment options in the market accompanied by no specific drug for the treatment of the disease, and the majority of patients suffering from celiac disease cases remain underdiagnosed/misdiagnosed acts as the major factors among others that will obstruct the market growth, and will further challenge the growth of celiac disease treatment market during the forecast period.

Growth Factors.

  • Rising prevalence of diabetes.

One of the prime factors which are expected to drive the market for celiac disease is the growing prevalence of diabetes among all age groups. Diabetes is a blood-glucose chronic disease in which the body is unable to produce the required amount of blood glucose, or as scientifically known as insulin. Both excess and low insulin levels are harmful to the body. The rising prevalence of diabetes has raised serious concerns among government and healthcare organizations. A report published by the World Health Organization (WHO) shows that 1.5 million people faced death owing to diabetes. This chronic disease is also widely prevalent among children and adolescents, causing health problems. increasing diabetes cases has significantly raised the risk of Celia disease, creating market demand for celiac disease treatment.

Impact of COVID – 19.

The COVID-19 pandemic is expected to have a positive impact on the Celiac disease treatment market. This growth can be mainly attributed to two factors i.e., staying home and stockpiling of food due to the fear of supermarket closures and reduced supply from food manufacturers.  The lockdowns imposed because of the pandemic led to prolonged isolation in one’s house as well as a steep decrease in body movement due to movement restrictions. Additionally, due to stockpiling of food, which is expected to be mostly junk food, because of its long shelf life, has led to an increase in its consumption, further expected to celiac disease. Therefore, due to the pandemic-imposed restrictions on movement and change in diet due to inadequate food supply and temporary closures of supermarkets, the risk of celiac disease is on the rise, which is expected to substantially propel its treatment market growth, in the upcoming years.

Competitive Insights.

The increasing need for celiac disease treatment caused by the rising occurrence of celiac disease due to changing lifestyles and the increasing prevalence of diabetes across the world has led to the entry of several new players like BioLineRx in the celiac disease treatment market. The entry of these new players in a market where traditional pharma behemoths like General Mills, Inc. and Glenmark Pharmaceuticals Inc. already exist, is expected to lead to further innovation in the trocars market. Moreover, to further increase their clientele as well as increase their market share in the upcoming years, many of these market players have taken various strategic actions like partnerships and the development of novel solutions which primarily focus on providing comfort to the patient, which is expected to keep the market competitive and constantly evolving.

Celiac Disease Treatment Market Scope:

Report Metric Details
 Market size value in 2019  US$218.303 million
 Market size value in 2026  US$561.677 million
 Growth Rate  CAGR of 14.45% from 2019 to 2026
 Base year  2019
 Forecast period  2021–2026
 Forecast Unit (Value)  USD Million
 Segments covered  Type, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered  BioLineRx, ImmunogenX, Calypso Biotech SA, Freedom Foods Group Limited,   General  Mills, Inc., Glenmark Pharmaceuticals Inc., Hain Celestial Group, Inc.,   Innovate   Biopharmaceuticals Inc., Kellogg Company, Mondelez International Inc.
 Customization scope  Free report customization with purchase



  • By Type
    • Vitamins and dietary supplements
    • Steroids and immunosuppressive drugs
    • Therapeutic vaccines
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • UK
      • Germany
      • Italy
      • Spain
      • Others
    • Middle East and Africa
      • Israel
      • Saudi Arabia
      • Others
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Taiwan
      • Thailand
      • Indonesia
      • Others

Frequently Asked Questions (FAQs)

Q1. What will be the celiac disease treatment market size by 2026?
A1. The celiac disease treatment market is expected to reach a total market size of US$561.677 million by 2026.

Q2. What is the size of global celiac disease treatment market?
A2. Celiac Disease Treatment Market was valued at US$218.303 million in 2019.

Q3. What are the growth prospects for the celiac disease treatment market?
A3. The global celiac disease treatment market is expected to grow at a CAGR of 14.45% during the forecast period.

Q4. Who are the major players in the celiac disease treatment market?
A4. Prominent key market players in the celiac disease treatment market include BioLineRx, ImmunogenX, Calypso Biotech SA, Freedom Foods Group Limited, General Mills, Inc., Glenmark Pharmaceuticals Inc., among others.

Q5. What factors are anticipated to drive the celiac disease treatment market growth?
A5. The rising prevalence of diabetes across the world is expected to act as a major boosting factor for the celiac disease treatment market.

1. Introduction
1.1. Market Definition
1.2. Market Segmentation

2. Research Methodology
2.1. Research Data
2.2. Assumptions

3. Executive Summary
3.1. Research Highlights

4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Function
4.4. Function Value Chain Analysis

5. Celiac Disease Treatment Market Analysis, By Type
5.1. Introduction
5.2. Vitamins and dietary supplements
5.3. Steroids and immunosuppressive drugs
5.4. Therapeutic vaccines

6. Celiac Disease Treatment Market Analysis, By Geography  
6.1. Introduction
6.2. North America  
6.2.1.  United States
6.2.2.  Canada
6.2.3.  Mexico
6.3. South America  
6.3.1.  Brazil
6.3.2.  Argentina
6.3.3.  Others
6.4. Europe  
6.4.1.  UK
6.4.2.  Germany
6.4.3.  Italy
6.4.4.  Spain
6.4.5.  Others
6.5. The Middle East and Africa  
6.5.1.  Israel 
6.5.2.  Saudi Arabia
6.5.3.  Others
6.6. Asia Pacific  
6.6.1.  China
6.6.2.  Japan
6.6.3.  India
6.6.4.  Australia
6.6.5.  South Korea
6.6.6.  Taiwan
6.6.7.  Thailand
6.6.8.  Indonesia
6.6.9.  Others

7.  Competitive Environment and Analysis
7.1.  Major Players and Strategy Analysis
7.2.  Emerging Players and Market Lucrativeness
7.3.  Mergers, Acquisitions, Agreements, and Collaborations
7.4.  Vendor Competitiveness Matrix

8.  Company Profiles.
8.1. BioLineRx
8.2. ImmunogenX
8.3. Calypso Biotech SA 
8.4. Freedom Foods Group Limited 
8.5. General Mills, Inc. 
8.6. Glenmark Pharmaceuticals Inc. 
8.7. Hain Celestial Group, Inc. 
8.8. Innovate Biopharmaceuticals Inc. 
8.9. Kellogg Company 
8.10. Mondelez International Inc. 



Calypso Biotech SA

Freedom Foods Group Limited

General Mills, Inc.

Glenmark Pharmaceuticals Inc.

Hain Celestial Group, Inc.

Innovate Biopharmaceuticals Inc.

Kellogg Company

Mondelez International Inc.